Меню
Идёт набор NCT05717712

Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

Фаза I С лечением Oncolytic Virus Diffuse Intrinsic Pontine Glioma Adverse Drug Event

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Ad-TD-nsIL12.
Кому может быть актуально
Состояния в реестре: Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event. Базовые параметры: 1 год — 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients (NCI-CTCAE V5.0).

Вмешательства

  • Биопрепарат Ad-TD-nsIL12
    After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3 days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.

Первичные конечные точки

  • Safety of Ad-TD-nsIL12 intratumoral injection in primary pediatric DIPG patients. [Срок оценки: 3 months after virus injection]
Вторичные конечные точки (4)
  • Tumor response [Срок оценки: 3 months after virus injection]
  • Over-all survival (12 months) [Срок оценки: 12 months after virus injection]
  • QoL [Срок оценки: 2 years after virus injection]
  • Sample Collection [Срок оценки: 3 months after virus injection]

Критерии участия

Критерии включения

  • Informed consent of the parents or patient.
  • Patient must be, in the investigator opinion, able to comply with all the protocol procedures.
  • Age 1-18 years.
  • A negative pregnancy test in fertile women (women are considered of childbearing potential (WOCBP) after menarche, unless permanently infertile, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
  • Patient newly diagnosed of DIPG in MRI.
  • Pre-enrollment patients LPS (patients aged ≥1 and <16 years) and KPS (patients aged ≥16 years) ≥ 50.
  • Lesion considered by the investigator to be accessible for stereotactic biopsy. The location of the lesion allows injection without virus entering the ventricular system.
  • No previous treatment for DIPG.

Критерии исключения

  • Serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. Patients must be afebrile at baseline (<38℃).
  • Other investigational medications within 30 days prior to viral treatment.
  • Participants with immunodeficiency, autoimmune disease, or active hepatitis.
  • Any medical or psychological condition that might interfere with the patient's ability to participate if older than 16 years or parents ability when younger than 16, or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.
  • Tumor with multiple location.
  • Pregnant or breast-feeding females.
  • Severe bone marrow hypoplasia.
  • Transaminases (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin > 3 times the upper limit of normal.
  • Neutrophils < 1x10\^9/L.
  • Platelets ≤ 100x10\^9/L.
  • Hemoglobin < 9 g/dl.
  • Patients with Li-Fraumini syndrome or a known germline defect in the retinoblastoma gene or its associated pathways.
  • Administer any type of vaccine within 30 days prior to Ad-TD-nsIL12 administration.
  • Blood transfusions or drugs (such as G-CSF) within 28 days before baseline to treat pancytopenia or other blood disorders.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Китай · 1 центр
  • Sanbo Brain Hospital, Capital Medical University — Пекин

Публикации

  • Zhang Z, Zhang C, Miao J, Wang Z, Wang Z, Cheng Z, Wang P, Dunmall LSC, Lemoine NR, Wang Y. A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma. Cells. 2020 Nov 10;9(11):2438. doi: 10.3390/cells9112438. PMID 33182528
  • Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther. 2009 Apr;17(4):614-22. doi: 10.1038/mt.2009.9. Epub 2009 Feb 17. PMID 19223865
  • Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G, Cheng Z, Wang S, Dong J, Feng B, Chard LS, Lemoine NR, Wang Y. Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017 Nov 9;8(1):1395. doi: 10.1038/s41467-017-01385-8. PMID 29123084

Идентификаторы

NCT: NCT05717712 · Ad-TD-nsIL12 for primary DIPG

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗